Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
BioSpace1d
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
The Spokesman-Review4d
The Motley Fool: Not-so-bad cinical trial results
Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a phase 2 clinical trial for its weight-loss candidate MariTide.
pharmaphorum6d
Amgen's big reveal of obesity data falls a little flat
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
Healio28d
Novel drug confers weight loss of up to 20% at 1 year in phase 2 study
Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.
C&EN9d
Weight-loss start-up emerges from stealth
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...